At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TPST Tempest Therapeutics Inc.
Post-Market Trading 01-10 19:19:54 EST
0.9494
-0.0362
-3.67%
盘后0.9500
+0.0006+0.06%
18:17 EST
High0.9800
Low0.9010
Vol1.05M
Open0.9800
D1 Closing0.9856
Amplitude8.02%
Mkt Cap41.43M
Tradable Cap38.02M
Total Shares43.64M
T/O979.26K
T/O Rate2.61%
Tradable Shares40.05M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Tempest Receives Orphan Drug Designation From U.S. FDA For Amezalpat
Tempest Receives Orphan Drug Designation From the U.S. Food and Drug Administration for Amezalpat to Treat Patients With Hepatocellular Carcinoma (Hcc)
BRIEF-Tempest Receives FDA Study May Proceed For Pivotal Phase 3 Trial Of Amezalpat Combination Therapy For The Treatment Of First-Line Hepatocellular Carcinoma
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.